newsfilter
← Latest News
GlobeNewswire·

EyePoint Announces Participation at Upcoming Investor Conferences and Scientific Meetings

  • EyePoint, Inc. (Nasdaq: EYPT) will present at four investor conferences in November 2026: Guggenheim Healthcare Innovation Conference on Nov. 9, Stifel Healthcare Conference on Nov. 10, Jefferies Global Healthcare Conference in London on Nov. 16, and UBS Global Biopharma Conference on Nov. 17.
  • All investor conference sessions are Fireside Chats scheduled between 1:20 pm EST and 3:00 pm GMT, with webcasts available via the company website at www.eyepoint.bio.
  • EyePoint will participate in the Eyenovate at FLORetina scientific meeting on December 3, 2026, featuring presentations on the LUCIA Phase 3 trial results for wet AMD and the COMO/CAPRI trials for diabetic macular edema (DME) by Dr. Anat Loewenstein and Dr. Ramiro Ribeiro.
  • Presentations at the FLORetina-ICOOR 2026 Congress will occur on December 4-5, 2026, covering the management of macular disease with EYP-1901, including updates from Dr. Tarek S. Hassan, Dr. David S. Boyer, and Dr. Charles C. Wykoff.
  • Scientific meeting presentations will be posted in the Scientific Publications section of www.eyepoint.bio following each event.
  • The company's lead product candidate, DURAVYU™ (EYP-1901), combines vorolanib with the Durasert E™ sustained-delivery technology for the treatment of serious retinal diseases.
  • DURAVYU is currently under evaluation in Phase 3 pivotal trials for diabetic macular edema (DME) and has received conditional FDA acceptance as its proprietary name.
  • Vorolanib is exclusively licensed to EyePoint by Equinox Sciences, a Betta Pharmaceuticals affiliate, for ophthalmic use outside of China, Macao, Hong Kong, and Taiwan.
  • EyePoint is headquartered in Watertown, Massachusetts, with a commercial manufacturing facility in Northbridge, Massachusetts.
Company
EyePoint, Inc.
Keywords
Nasdaq:EYPT, EyePoint, Inc.